Physician profile
Mechelle Patrick
NPI 1861410342
$8,205.79
in general payments reported to CMS, 2019-2025
44 companies · $1,531 in 2025
The $1,531 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,302 · 2022: $1,784 · 2023: $1,104 · 2024: $1,485 · 2025: $1,531.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,106 · Entertainment: $13.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,105.90 |
| Entertainment | $13.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,306.86 | 2021-2025 | |
| Novo Nordisk INC | $1,072.47 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Esperion Therapeutics, INC. | $976.29 | 2021-2024 | Nexletol |
| Astrazeneca Pharmaceuticals LP | $790.69 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $743.86 | 2021-2025 | Mounjaro, Trulicity, Zepbound |
| Pfizer INC. | $491.46 | 2021-2025 | |
| Glaxosmithkline, LLC. | $344.78 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $274.37 | 2021-2025 | Repatha, Otezla, Otezla |
| Biohaven Pharmaceuticals, INC. | $192.53 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $156.70 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $154.85 | 2021-2023 | Jardiance |
| Astellas Pharma US INC | $136.38 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $127.28 | 2023-2025 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $125.50 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $113.50 | 2021-2025 | Xifaxan |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mechelle Patrick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.